Literature DB >> 22155237

The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.

Kobra Haghighi1, Tracy Pritchard, Julie Bossuyt, Jason R Waggoner, Qunying Yuan, Guo-Chang Fan, Hanna Osinska, Ahmad Anjak, Jack Rubinstein, Jeffrey Robbins, Donald M Bers, Evangelia G Kranias.   

Abstract

Depressed Ca-handling in cardiomyocytes is frequently attributed to impaired sarcoplasmic reticulum (SR) function in human and experimental heart failure. Phospholamban (PLN) is a key regulator of SR and cardiac function, and PLN mutations in humans have been associated with dilated cardiomyopathy (DCM). We previously reported the deletion of the highly conserved amino acid residue arginine 14 (nucleic acids 39, 40 and 41) in DCM patients. This basic amino acid is important in maintaining the upstream consensus sequence for PKA phosphorylation of Ser 16 in PLN. To assess the function of this mutant PLN, we introduced the PLN-R14Del in cardiac myocytes of the PLN null mouse. Transgenic lines expressing mutant PLN-R14Del at similar protein levels to wild types exhibited no inhibition of the initial rates of oxalate-facilitated SR Ca uptake compared to PLN-knockouts (PLN-KO). The contractile parameters and Ca-kinetics also remained highly stimulated in PLN-R14Del cardiomyocytes, similar to PLN-KO, and isoproterenol did not further stimulate these hyper-contractile basal parameters. Consistent with the lack of inhibition on SR Ca-transport and contractility, confocal microscopy indicated that the PLN-R14Del failed to co-localize with SERCA2a. Moreover, PLN-R14Del did not co-immunoprecipitate with SERCA2a (as did WT-PLN), but rather co-immunoprecipitated with the sarcolemmal Na/K-ATPase (NKA) and stimulated NKA activity. In addition, studies in HEK cells indicated significant fluorescence resonance energy transfer between PLN-R14Del-YFP and NKAα1-CFP, but not with the NKA regulator phospholemman. Despite the enhanced cardiac function in PLN-R14Del hearts (as in PLN-knockouts), there was cardiac hypertrophy (unlike PLN-KO) coupled with activation of Akt and the MAPK pathways. Thus, human PLN-R14Del is misrouted to the sarcolemma, in the absence of endogenous PLN, and alters NKA activity, leading to cardiac remodeling.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155237      PMCID: PMC3376549          DOI: 10.1016/j.yjmcc.2011.11.012

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  45 in total

1.  Phospholamban ablation and compensatory responses in the mammalian heart.

Authors:  G Chu; D G Ferguson; I Edes; E Kiss; Y Sato; E G Kranias
Journal:  Ann N Y Acad Sci       Date:  1998-09-16       Impact factor: 5.691

Review 2.  Phospholamban and cardiac contractile function.

Authors:  A G Brittsan; E G Kranias
Journal:  J Mol Cell Cardiol       Date:  2000-12       Impact factor: 5.000

3.  Regulation of Na/K-ATPase beta1-subunit gene expression by ouabain and other hypertrophic stimuli in neonatal rat cardiac myocytes.

Authors:  P Kometiani; J Tian; J Li; Z Nabih; G Gick; Z Xie
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

Review 4.  Structural similarities of Na,K-ATPase and SERCA, the Ca(2+)-ATPase of the sarcoplasmic reticulum.

Authors:  K J Sweadner; C Donnet
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

5.  Na(+)/K(+)-ATPase as a signal transducer.

Authors:  Zijian Xie; Amir Askari
Journal:  Eur J Biochem       Date:  2002-05

Review 6.  Cardiotonic steroids: potential endogenous sodium pump ligands with diverse function.

Authors:  Renata I Dmitrieva; Peter A Doris
Journal:  Exp Biol Med (Maywood)       Date:  2002-09

7.  A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta -agonists.

Authors:  G Chu; J W Lester; K B Young; W Luo; J Zhai; E G Kranias
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

8.  The enhanced contractility of the phospholamban-deficient mouse heart persists with aging.

Authors:  J P Slack; I L Grupp; R Dash; D Holder; A Schmidt; M J Gerst; T Tamura; C Tilgmann; P F James; R Johnson; A M Gerdes; E G Kranias
Journal:  J Mol Cell Cardiol       Date:  2001-05       Impact factor: 5.000

9.  Maximal inhibition of SERCA2 Ca(2+) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban.

Authors:  A G Brittsan; A N Carr; A G Schmidt; E G Kranias
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

10.  Chronic SR Ca2+-ATPase inhibition causes adaptive changes in cellular Ca2+ transport.

Authors:  Angela G Brittsan; Kenneth S Ginsburg; Guoxiang Chu; Atsuko Yatani; Beata M Wolska; Albrecht G Schmidt; Michio Asahi; David H MacLennan; Donald M Bers; Evangelia G Kranias
Journal:  Circ Res       Date:  2003-03-13       Impact factor: 17.367

View more
  30 in total

Review 1.  Mechanisms of altered Ca²⁺ handling in heart failure.

Authors:  Min Luo; Mark E Anderson
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

2.  Dysfunctional conformational dynamics of protein kinase A induced by a lethal mutant of phospholamban hinder phosphorylation.

Authors:  Jonggul Kim; Larry R Masterson; Alessandro Cembran; Raffaello Verardi; Lei Shi; Jiali Gao; Susan S Taylor; Gianluigi Veglia
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

Review 3.  Peptides encoded by noncoding genes: challenges and perspectives.

Authors:  Shuo Wang; Chuanbin Mao; Shanrong Liu
Journal:  Signal Transduct Target Ther       Date:  2019-12-13

4.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

5.  Effects of naturally occurring arginine 14 deletion on phospholamban conformational dynamics and membrane interactions.

Authors:  Vitaly V Vostrikov; Kailey J Soller; Kim N Ha; T Gopinath; Gianluigi Veglia
Journal:  Biochim Biophys Acta       Date:  2014-09-22

6.  Phospholamban regulates nuclear Ca2+ stores and inositol 1,4,5-trisphosphate mediated nuclear Ca2+ cycling in cardiomyocytes.

Authors:  Mu Chen; Dongzhu Xu; Adonis Z Wu; Evangelia Kranias; Shien-Fong Lin; Peng-Sheng Chen; Zhenhui Chen
Journal:  J Mol Cell Cardiol       Date:  2018-09-24       Impact factor: 5.000

7.  Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A.

Authors:  Delaine K Ceholski; Catharine A Trieber; Charles F B Holmes; Howard S Young
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

8.  Calcium Uptake in Crude Tissue Preparation.

Authors:  Philip A Bidwell; Evangelia G Kranias
Journal:  Methods Mol Biol       Date:  2016

Review 9.  Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend.

Authors:  Kobra Haghighi; Philip Bidwell; Evangelia G Kranias
Journal:  J Mol Cell Cardiol       Date:  2014-10-18       Impact factor: 5.000

Review 10.  Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome.

Authors:  Evangelia G Kranias; Roger J Hajjar
Journal:  Circ Res       Date:  2012-06-08       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.